Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer

• Status: Completed
• Trial end date: 2009-09-01
• Target enrollment: 0
• Participant gender: Male

Summary

The objective of this study is to assess the effect Of zoledronic acid on circulating and bone marrow-residing prostate cancer cells in patients with clinically localized prostate cancer

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Collaborator: University of Athens
• Treatments: Diphosphonates; Zoledronic Acid

Criteria

Inclusion Criteria

• Prostate cancer

• Radical prostatectomy or external beam irradiation therapy within 6 months before study entry.

• No bone metastases according to bone scan

Exclusion Criteria

• Metastatic prostate cancer

• Hormone ablation therapy for more than 3 months before/after radical prostatectomy and external beam irradiation therapy

• Treatment with bisphosphonates or other drugs known to affect the skeleton within the past year.

Other protocol-defined inclusion / exclusion criteria may apply.